A Single Dose, Three-Arm, Placebo-Controlled, Phase I Study of the Bradykinin B2 Receptor Antagonist Anatibant (LF16-0687Ms) in Patients with Severe Traumatic Brain Injury
Journal article published in 2005 by
Anthony Marmarou,
Martine Guy,
Laine Murphey,
Francis Roy,
Laure Layani,
Jean-Philippe Combal,
Claude Marquer
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 